skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Rachelle S. Doody, M.D., Ph.D.

Professor of Neurology

Effie Marie Cain Chair in Alzheimer's Disease Research

Director, Alzheimer's Disease and Memory Disorders Center

Clinical Service Area

Neurology

Specialty

Alzheimer's Disease
Memory Disorders

Board Certification

American Board of Psychiatry and Neurology, Neurology

Clinic Appointments

713-798-4734

Consult

713-798-4734

Medical School

M.D./Ph.D., Baylor College of Medicine, Houston, Texas

Internship

Internal Medicine, McGill University Faculty of Medicine, Montreal, QC

Residency

Neurology, Baylor College of Medicine, Houston, Texas

Clinic Location

Baylor Neurology
The Medical Building
1977 Butler Blvd., Suite E5.101
Houston, Texas 77030

Clinical Interests

Alzheimer's disease, neurodegenerative dementias, ischernic vascular dementia, memory loss, mild cognitive impairment

Research Interests

Cognitive aspects of Alzheimer's disease, dementia, and aphasia. Alzheimer's Disease therapeutics and modeling of progression for clinical prognostication, validation of biological markers, and enhancing design of AD clinical trials

Contact Information

Rachelle S. Doody, M.D., Ph.D.
Department of Neurology
Baylor College of Medicine
1977 Butler Blvd., Suite E5.101
Houston, Texas 77030

Tel: 713-798-7416
Fax: 713-798-5326
Email:

BCM Honors

  • Distinguished faculty, 2011.

Awards

  • Listed annually in Best Doctors in America, Central Region, 1996-present.
  • Houston Healthcare Heroes, 2009.
  • Distinguished alumni, Rice University, Houston, TX, 2009.
  • Zenith Award National Alzheimer's Association, 2002.

Journal Publications (Selected out of 151)

  • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-21. [View journal article]
  • O'Bryant SE, Xiao G, Barber R, Cullum CM, Weiner M, Hall J, et al. Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014;37(1-2):45-57. [View journal article]
  • Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(17):1661. [View journal article]
  • Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341-50. [View journal article]
  • Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther. 2013;5(1):12. [View journal article]
  • O'Bryant SE, Xiao G, Barber R, Cullum CM, Weiner M, Hall J, et al. Molecular Neuropsychology: Creation of Test-Specific Blood Biomarker Algorithms. Dement Geriatr Cogn Disord. 2013;37(1-2):45-57. [View journal article]
  • Pavlik V, Massman P, Barber R, Doody R. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013;34(2):449-56. [View journal article]
  • Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013;9(3):338-45. [View journal article]
  • Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013;13:56. [View journal article]
  • Senanarong V, Harnphadungkit K, Poungvarin N, Vannasaeng S, Chongwisal S, Chakorn T, et al. The dementia and disability project in Thai elderly: rational, design, methodology and early results. BMC Neurol. 2013;13:3. [View journal article]

Books and Volumes

  • Doody RS, editor. Alzheimer's dementia. Delray Beach (FLA): Carma Publishing; 2008.

Book Chapters and Other Publications (Selected out of 16)

  • Doody RS. Prevention and future treatment of Alzheimer's disease. In: Doody RS, editor. Alzheimer's dementia. Delray Beach (FLA): Carma Publishing; 2008. p. 115-140.
  • Doody RS. Alzheimer's disease. In: Johnson RT, Griffin JW, McArthur JC, editors. Current therapy in neurologic disease. 7th ed. Philadelphia: Mosby, Inc.; 2006. p. 311-314.
  • Doody RS, Winblad B, Jelic V. Alzheimer's and related disorders annual 2003. In: Gauthier S, Scheltens P, Cummings J, editors. Neurodegenerative dementias. London: Martin Dunitz (Taylor & Francis); 2004. p. 137-144.
  • Doody RS. Pathogenesis and treatment strategies for selected therapies in Alzheimer's disease. In: Iqbal K, Winblad B, editors. Alzheimer's disease and related disorders: research advances. Vol. 57. Bucharest, Romania: Ana Aslan International Academy of Aging; 2003. p. 633-638.
  • Grundman M, Kim H, Salmon D, Storandt M, Smith G, Ferris S, et al. The Alzheimer's disease center's neuropsychological database initiative: a resource for Alzheimer's disease prevention trials. In: Iqbal K, Sisodiya S, Winblad B, editors. Alzheimer's disease: advances in etiology, pathogenesis, therapeutics. New York: John Wiley & Sons; 2001. p. 129-140.
  • Doody RS. Treatment strategies in Alzheimer's disease. In: Trojanowski J, Clark C, editors. Neurodegenerative dementias. New York: McGraw-Hill; 2000. p. 115-126.
  • Hanna P, Doody RS. Alien limb syndrome. In: Litvan I, Goetz C, Lang A, editors. Corticobasal degeneration. 51st ed. Philadelphia: Lippincott-Raven, Inc.; 2000. p. 135-145.
  • Doody RS. Alzheimer's disease. In: Rakel R, editor. Conn's current therapy. 51st ed. Philadelphia: WB Saunders; 1999. p. 878-882.
  • Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. In: Vellas B, Fitten L, editors. Research and practice in AD. 51st ed. Paris: Serdi Publishing; 1999. p. 270-275.
  • Doody RS, Davidson M, Shoulson I, Whitehouse P. Harmonization of drug approval guidelines in Alzheimer's and Parkinson's diseases. In: Fisher A, Yorshida M, Hanin I, editors. Progress in Alzheimer's and Parkinson's diseases. New York: Plenum Press; 1998. p. 861-865.

Poster and Platform Presentations (Selected out of 130)

  • Alverson WA, Massman PJ, Grabyan JM, Doody RS. Progression and stability of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Int Neuropsychol Soc. 2014;20(Suppl S1):.
  • Doody R, Cutler A, D'Amico S, Zorowitz R, Alexander D, Hammond F, et al. A study to assess the safety, tolerability, and effectiveness of nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II]. Presented at the 2013 Alzheimer's Association International Conference (AAIC), Boston, Mass. (July 13-18, 2013). [View poster]
  • Biernot J, Darby E, Chan W, Pavlik V, Doody R. Examining anti-dementia drug persistence in Alzheimer's disease (AD) patients. Neurology. 2013;80(Meeting Abstracts 1):P07.140. [View poster]
  • Grabyan JM, Massman PJ, Alverson W, Doody RS. A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients. J Int Neuropsychol Soc. 2013;19(Suppl S1):214.
  • Lowe DA, Balsis S, Miller T, Benge JF, Doody RS. Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes. J Int Neuropsychol Soc. 2013;19(Suppl S1):128-9.
  • Szigeti K, Lal D, Li Y, Doody RS, Yan L. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. Ann Neurol. 2012;72 Suppl 16:S134-5. [Platform Presentation]
  • Doody R, Chan W, Pavlik V, Rountree S, Massman P. Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures. Presented at the Alzheimer's Association International Conference (AAIC), Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012).
  • McGee JS, Nguyen A, Darby E, Chan W, Pavlik V, Doody R. Factors influencing time to nursing home placement in persons with probable Alzheimer's disease. Presented at the Alzheimer's Association International Conference (AAIC), Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012). [View poster]
  • Rountree S, Chan W, Pavlik V, Doody R. Factors that influence long term care placement in an Alzheimer disease cohort. Presented at the Alzheimer's Association International Conference (AAIC), Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012). [View poster]
  • Winblad B, Doody R, Cummings J, Tariot P, Sano M, Aisen P, et al. Dimebon in Alzheimer's disease: Summary and contract of three efficacy trials. Presented at the Alzheimer's Association International Conference (AAIC), Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012).

E-mail this page to a friend